AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06491680 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin 10mg Tab
Description: Dapagliflozin 10 mg tablet orally, once daily. Started 7 days before the first cycle of anthracyclines till the end of last anthracyclines dose.~taken orally, once daily. Started from 5 to 7 days before the first cycle of anthracyclines till the end of last anthracycline dose.
Study NCT06336057 — intervention group
Intervention type: BEHAVIORAL
Intervention: Mentalization
Description: complete several questionnaires including the RFQ (reflective functioning questionnaire) and the MST (Mental states task) which are validated questionnaires about mentalization
Study NCT05341791 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cartoon video describing study information notice
Description: The video will be 20-minutes long, and will consist of graphic depictions (in cartoon style) of the study information content presented in the same flow as the written notice, and explained by a voice-over in the background. The participant will view the video in a quiet room, on a tablet provided by the study staff. The participant will be able to pause the video or rewind it as needed, and view it at his/her desired pace. The video will have an embedded knowledge check at the end of each section, consisting of a background voice asking some questions, pausing (for the participant to think through the correct answers) and then providing the right answers.
Study NCT05886088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LID104
Description: Experimental
Study NCT05886088 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: Active comparator
Study NCT05886088 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linagliptin
Description: Active comparator
Study NCT05307679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basmisanil
Description: Participants will receive oral basmisanil at age-appropriate dosages
Study NCT05307679 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive oral placebo
Study NCT04872387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2586116
Description: Nasal administration
Study NCT04872387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo
Study NCT05119075 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dopaminergic OFF-drug state
Description: Dopaminergic OFF-drug state: Overnight withdrawal of dopaminergic antiparkinsonian drugs during visit 3 or 4. The sequence of drug conditions (dopaminergic OFF-drug/ON-drug state or ON-drug/OFF-drug state) will be randomized.
Study NCT05119075 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dopaminergic ON-drug state
Description: Dopaminergic ON-drug state: Patient will be evaluated in his/her regular treatment in dopaminergic ON-drug state at visit 3 or 4. The sequence of drug conditions (dopaminergic OFF-drug/ON-drug state or ON-drug/OFF-drug state) will be randomized.
Study NCT04939649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: A sub-anaesthetic dose of ketamine will be administered for up to a four-week course of twice-weekly infusions.
Study NCT04939649 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: A sub-anaesthetic dose of midazolam will be administered for up to a four-week course of twice-weekly infusions.
Study NCT06222710 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pharmacoacupuncture with ultrasound guiding
Description: Physician choose the adequate type and dose of pharmacoacupuncture and needle type with ultrasound guiding
Study NCT06222710 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacoacupuncture without ultrasound guiding
Description: Physician choose the adequate type and dose of pharmacoacupuncture and needle type without ultrasound guiding
Study NCT06386887 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intermittent Fasting
Description: Intermittent fasting (IF) also known as time restricted eating regimen consisting of 16 hours of fasting and 8 hours of ad libitum feeding for 5 days followed by ad libitum feeding for 2 days has been proposed. With this type of intervention, there are no dietary restrictions to the type or quality of food and it decreased daily energy intake by 20%. Participants will be asked to follow an IF schedule consisting of 16 hour of continuous fasting per day for 5 days a week. This will be started 2 days prior to chemotherapy (cycle 2).
Study NCT06386887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Description: Chemotherapy will be given as standard treatment every 3 weeks (21 days) and continue for 3 to 4 cycles per routine care. As chemotherapy is not part of this research study, participants will begin standard chemotherapy as decided by their physician.
Study NCT06386887 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neoadjuvant chemotherapy
Description: Chemotherapy will be given as standard treatment every 3 weeks (21 days) and continue for 3 to 4 cycles per routine care. As chemotherapy is not part of this research study, participants will begin standard chemotherapy as decided by their physician.
Study NCT05412082 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiation therapy
Description: MRI-guided pelvic IMRT to the Planning Tumor Volume (PTV) at a dose of 50 Grays (gy) delivered in 25 fractions (fx) over 5 weeks.
Study NCT05412082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: 5-FU dose of 400 mg/m2 will be administered intravenously (IV) over 5-15 minutes beginning on Day 1; then a dose of 2400 mg/m2 via continual infusion (CI) over 4446-478 hours total dose during Days 1 and 2 of every 14-day cycle, for 4 to 6 cycles.~During SMART TNT Plan I, 5-FU dose of 225 mg/m2 per day will be administered via CI on Day 1 radiation therapy, delivered either 5 or 7 days per week.
Study NCT05412082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Leucovorin dose of 400 mg/m2 bolus will be administered intravenously (IV) on Day 1 of each 14-day cycle for 4 to 6 cycles, prior to SMART TNT Plan I radiation therapy.
Study NCT05450172 — intervention group
Intervention type: OTHER
Intervention: QoR-15 questionnaire
Description: The QoR-15 is a 15-item questionnaire on postoperative quality of recovery. The DN4 is a 10-item questionnaire on neuropathic pain. Both questionnaires will be given to the patients preoperatively, on postoperative days 2 and 3, and 1, 3 and 6 months after surgery.
Study NCT05412082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin dose of 85 mg/m2 will be administered intravenously (IV) on Day 1 of each 14-day cycle for 4 - 6 cycles.
Study NCT05412082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine will be administered orally at a dose of 825 mg/m2 via tablet twice per day (BID) on Day 1, 5 days per week.
Study NCT05412082 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Accelerated Radiation Therapy
Description: MRI-guided Pelvic accelerated radiation therapy (ART) given over one week at one of the following dose levels :~* Dose level -1: 10 Gy delivered in 4 fractions~* Dose level 0: 12 Gy delivered in 4 fractions~* Dose level 1: 14 Gy delivered in 4 fractions~* Dose level 2: 16 Gy in delivered 4 fractions
Study NCT05412082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan dose of 180 mg/m2 will be administered intravenously (IV) on Day 1 of each 14-day cycle for 4 to 6 cycles, prior to SMART TNT Plan I radiation therapy.
Study NCT06531824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 690517
Description: BI 690517
Study NCT06531824 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo matching BI 690517
Description: Placebo matching BI 690517
Study NCT06531824 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching BI 690517
Description: Placebo matching BI 690517
Study NCT06531824 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Empagliflozin
Description: Empagliflozin
Study NCT06531824 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Empagliflozin
Description: Empagliflozin
Study NCT06531824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: Empagliflozin
Study NCT04693533 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Fremanezumab Prefilled Syringe [Ajovy]
Description: The treatment is 225 mg (dissolved in 1.5 ml saline) fremanezumab. Fremanezumab (Ajovy) is a month-long-acting anti-CGRP injection that patients are taught to self-administer at home.
Study NCT05121441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARD-101
Description: Twice daily, oral administration
Study NCT05121441 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Twice daily, oral administration
Study NCT06585566 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cortical-shell graft
Description: Retromolar cortical shell graft technique for SABG
Study NCT04994938 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet Intervention
Description: Participants will engage in discussions about healthy eating one time per week led by a trained peer leader for 12-weeks.
Study NCT04994938 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Participants will participate in a group exercise session led by a trained peer leader 2-times per week for 12-weeks.
Study NCT05167864 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Onabotulinumtoxina for Injection
Description: cosmetic injection into the glabella area (eyebrow area)
Study NCT05167864 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abobotulinumtoxina for Injection
Description: cosmetic injection into the glabella area (eyebrow area)
Study NCT05167864 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IncobotulinumtoxinA for Injection
Description: cosmetic injection into the glabella area (eyebrow area)
Study NCT05167864 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PrabotulinumtoxinA for Injection
Description: cosmetic injection into the glabella area (eyebrow area)
Study NCT05773157 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Online Modules
Description: Participants receive modules to improve responsive feeding practices of caregivers
Study NCT05278208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LUTATHERA® (Lutetium Lu 177 dotatate)
Description: Lutathera: IV administration maximum dose of 200 mCi once every 8 weeks (one cycle) for total of 4 cycles (8 months)
Study NCT06494774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1815368
Description: BI 1815368
Study NCT06494774 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching BI 1815368
Description: Placebo matching BI 1815368
Study NCT05197790 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: FDA approved pulse oximeter and DOVE device prototype
Description: The objective is to assess reasonable detection of hypoxic episodes
Study NCT04745520 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rib fixation
Description: Rib fixation is performed by a senior surgeon. The patient is under general anesthesia. A thoracotomy focused on the fracture is performed to optimize access to the rib to be repaired. Video-assisted thoracic surgery (VATS) can be performed to better localize rib fractures. Significant muscle division is avoided. Removal of the periosteum is not required. The broken rib segments are approximated with forceps and the medical devices are used to fix the fracture. The medical devices are implemented according to the manufacturers' recommendations. The goal is to stabilize the chest wall. It is not useful to fix all fractures to stabilize the wall. A chest tube can be placed at the end of the operation.~Medical devices~The following medical devices can be used:~* MatrixRIB™, De Puy Synthes Companies, Zuchwill, Switzerland~* STRATOS™, MedXpert GmbH, Heitersheim, Germany~* NiTi Fixing PlatesTM, IAWAI, Yandzhou, China
Study NCT04745520 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Analgesia
Description: Epidural analgesia is continuing for 24 to 72 hours post-randomization to maximize outcome benefits. Afterwards, paracetamol, NSAID and/or opioid treatment are used according to pain severity. In case of opioid use, morphine treatment is preferred. However, other opioid drugs or doses can be considered to better customize the treatment.
Study NCT04745520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Analgesia
Description: Epidural analgesia is continuing for 24 to 72 hours post-randomization to maximize outcome benefits. Afterwards, paracetamol, NSAID and/or opioid treatment are used according to pain severity. In case of opioid use, morphine treatment is preferred. However, other opioid drugs or doses can be considered to better customize the treatment.
Study NCT06418204 — intervention group
Intervention type: OTHER
Intervention: Non-interventional Study
Description: Non-interventional study
Study NCT05050084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Description: Anti-androgen
Study NCT05050084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buserelin
Description: GnRH agonist
Study NCT05050084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darolutamide
Description: Anti-androgen
Study NCT05050084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: GnRH antagonist
Study NCT06071117 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Glasses (VR)
Description: Children allocated to this group will be distracted using VR glasses during dental treatment which is an individual headset that has earphones incorporated. Age-appropriate cartoons and movies will be shown to the children. The VR glasses will be then introduced to the children. The children will be given time to accommodate with the device before starting the procedure. The VR glasses will be applied during the dental examination and treatment.
Study NCT06071117 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: White noise
Description: Wireless kids' headphones will be introduced to the children allocated to this group. They will be given some time to accommodate with the headphones. Then, the white noise will be played and children will be asked to concentrate on the music during the procedure.~White noise stimulus will be set at 70 decibels, within the normal conversation volume range and below what is considered harmful to hearing. The white noise of rain sound, managed with an iPhone application called Muse. The decibel level of white noise will be calibrated using a portable digital sound level meter
Study NCT06071117 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Basic behavior management techniques
Description: Children allocated to this group will be managed by the basic behavior guidance techniques: (Tell-Show-Do). No adjunctive distraction tool will be used.
Study NCT03952962 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Abbott Laboratories Infinity™ implantable deep brain stimulation system
Description: Deep brain stimulation (DBS) refers to the process of delivering an electrical current to a precise location in the brain.
Study NCT05050084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flutamide
Description: Anti-androgen
Study NCT04452851 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BREATHE
Description: The on-demand handheld portable noninvasive positive pressure airway device unit generates BiPAP by using a built-in blower which intakes air from the nearby ambient. The BiPAP pressure functions as a virtual stent within the lungs of a user with COPD. The virtual stent opens the passageways within the user lungs. Once opened, the virtual stent facilitates gas exchange in order to relieve dyspnea. By temporarily facilitating this gas exchange, the user will quickly recover from dyspnea in order to resume regular activities.
Study NCT04452851 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BiPAP
Description: BiPAP stands for Bilevel Positive Airway Pressure, and is very similar in function and design to a CPAP machine (continuous positive airway pressure). A BiPAP machine is a non-invasive form of therapy for patients suffering from sleep apnea.
Study NCT04452851 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: COPD Inhaler
Description: Inhaler medication to support quick relief from COPD symptoms
Study NCT06319729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDD-2105
Description: A Chinese herbal medicine formula containing four granular herbs.
Study NCT06319729 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT06442722 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DDH with capsulorrhaphy
Description: group will undergo capsulorrhaphy, a surgical procedure to tighten the hip capsule ,
Study NCT06442722 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DDH without capsulorrhaphy
Description: group will not undergo capsulorrhaphy, a surgical procedure without tightness the hip capsule
Study NCT05050084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin
Description: GnRH agonist
Study NCT05050084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Histrelin
Description: GnRH agonist
Study NCT05050084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide
Description: GnRH agonist
Study NCT05050084 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo RT
Study NCT05050084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relugolix
Description: GnRH antagonist
Study NCT05050084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin
Description: GnRH agonist
Study NCT05296304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bexarotene
Description: Orally every day starting at the dose of 150 mg/day flat dose. At Day 15, if the treatment is tolerated, patients will escalate the dose of bexarotene to 300 mg/day, and that dose will remain constant during the rest of the study.
Study NCT05296304 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Skin Electron Beam (TSEB)
Description: At Day 21, if the bexarotene has shown to be tolerated, patients will receive the first dose of TSEB (2 Gy x 2).
Study NCT05238753 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive electromagnetic stimulation
Description: Non-invasive bilateral electromagnetic stimulation of the phrenic nerve
Study NCT04784078 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary Angiography and Intervention
Description: Transradial access puncture site
Study NCT04784078 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronary Angiography and Intervention
Description: Transradial access puncture site
Study NCT04852731 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardiac MRI
Description: Injected cardiac MRI
Study NCT04852731 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood collection
Description: Blood collection (including genetics at the inclusion visit)
Study NCT04852731 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prolongation of the MRI examination
Description: Prolongation of the MRI examination (4D flow sequence ; about 10 min)
Study NCT05316181 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HIPEC
Description: HIPEC perfusion, doxorubicin 35mg/m2 \& mitomycin 15 mg/m2, 41.5'C, 90 min.
Study NCT05405764 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Porcine protein supplement
Description: Porcine protein supplementation
Study NCT05405764 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control product maltodextrin supplement
Description: Maltodextrin supplementation
Study NCT05348044 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Res-ET intervention
Description: Remote IMST delivery on Resilience
Study NCT03905941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin 2000 mg/day will be used in this study. Metformin is a antihyperglycemic agent that is used as a first line medical therapy to treat type 2 diabetes mellitus. It is also used to prevent progression of impaired glucose tolerance. It decrease hepatic glucose production and increase insulin sensitivity.
Study NCT03905941 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin 2000 mg/day will be used in this study. Metformin is a antihyperglycemic agent that is used as a first line medical therapy to treat type 2 diabetes mellitus. It is also used to prevent progression of impaired glucose tolerance. It decrease hepatic glucose production and increase insulin sensitivity.
Study NCT03905941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral combined hormonal contraceptives
Description: Oral combined hormonal contraceptive (OCs) with a combination of ethinyl estradiol 20 mcg/norethindrone acetate 1 mg will be used in this study. OCs are normally used to prevent pregnancy by suppressing ovulation and to prevent endometrial hyperplasia by inducing regular withdrawal bleeding. OCs help control both clinical and biochemical hyperandrogenism in PCOS and are considered first line medical therapy until the age of menopause.